茂業國際(00848.HK)進一步出售重藥控股股份 套現8297萬元
格隆匯12月17日丨茂業國際(00848.HK)發佈公吿,繼先前出售事項後,公司間接持有82.80%權益的非全資附屬公司茂業商業於2021年12月6日至12月17日期間在公開市場上進一步出售1741.68萬股重藥控股(000950.SZ)股份,佔重藥控股截至該公吿日已發行股本約1.00%,總代價約為人民幣8297萬元(不包括交易成本),進一步出售事項有關的每股重藥控股股份的平均出售價約為人民幣4.76元。
先前出售事項完成後,公司間接持有的重藥控股的權益將由約3.48%減少至約2.65%;及進一步出售事項完成後,公司間接持有的重藥控股的權益將由約2.65%減少至約1.82%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.